Price T Rowe Associates Inc Halozyme Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,270,521 shares of HALO stock, worth $61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,270,521

Previous 1,301,687 2.39%

Holding current value

$61 Million

Previous $68.2 Million 6.7%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $1.6 Million - $2.01 Million	-31,166 Reduced 2.39%	1,270,521 $72.7 Million
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $107,493 - $148,973	2,843 Added 0.22%	1,301,687 $68.2 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $3.06 Million - $3.82 Million	-90,993 Reduced 6.55%	1,298,844 $52.8 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $5.93 Million - $7.5 Million	-178,074 Reduced 11.36%	1,389,837 $51.4 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $2.26 Million - $2.73 Million	-61,990 Reduced 3.8%	1,567,911 $59.9 Million
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $99,409 - $127,183	-3,283 Reduced 0.2%	1,629,901 $58.8 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $156,906 - $265,967	-4,775 Reduced 0.29%	1,633,184 $62.4 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $918,936 - $1.36 Million	22,939 Added 1.42%	1,637,959 $93.2 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.99 Million - $2.68 Million	51,663 Added 3.3%	1,615,020 $63.9 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $70,591 - $91,287	-1,890 Reduced 0.12%	1,563,357 $68.8 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $342,174 - $439,465	10,703 Added 0.69%	1,565,247 $62.4 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $1.26 Million - $1.61 Million	39,576 Added 2.61%	1,554,544 $62.5 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $305,490 - $368,621	-7,941 Reduced 0.52%	1,514,968 $61.6 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $381,175 - $503,556	9,814 Added 0.65%	1,522,909 $69.2 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $10.5 Million - $13.7 Million	266,361 Added 21.36%	1,513,095 $63.1 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $32.2 Million - $54.4 Million	1,246,734 New	1,246,734 $53.2 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.68B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Halozyme Therapeutics, Inc. Transaction History